BioSpace

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...
Labiotech.eu

Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...
BioSpaceOpinion

Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...
WTVD

Pfizer agrees to lower prescription drug costs for Medicaid in deal with President Donald Trump

WASHINGTON -- Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar ...

Pfizer raises 2025 profit forecast for second quarter in a row

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...
BioSpace

Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

Pfizer and Metsera Reach Deal Expected to Top $10 Billion

Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting ...